| Objective:To systematically evaluate the effectiveness and safety of idarubicin (IDA) and daunorubicin (DNR) combined with cytarabine to treating acute myeloid leukemia (AML).Methods:Randomized controlled trial (RCTs) of AML treated by IDA and DNR c ombined with cytarabine were electronically searched from PubMed (1966 to 2014), MEDLINE (1990 to 2014), CBM (1978 to 2014), CNKI (1979 to 2014), Wanfang Data (1998 to 2014), VIP (1991 to 2014). References of included studi-es were al so retrieved. The literature was independently screened according to exclusion and i nclusion criteria by two researchers independently and meta-analysis was conducted using Revman 5.2 software after date extraction and quality assessment.Results:13 RCTs were included involving 4347 patients. The results meta-analysis showed that:the group which was treated by idarubicin combined with cytarabine was superior to the daunorubicin combined with cytarabine in the aspects of overal 1 effectiveness rate [RR=1.18,95%CI(1.06,1.32), P=0.003], the significant effect iveness rate [RR=1.16,95%CI(1.07,1.27), P=0.0004], the recurrent rate [RR=0.5 1,95%Cl(0.34,0.94), P=0.03],but bone marrow suppression of IA is more obvi ous:(1).decrease in bone marrow blasts [MD=13.02,95%CI(9.81,16.23), P<0.00001], (2).the lowest value of WBC [MD=-0.22,95%C7(-038,-0.07), P=0.004], (3).the ti me of lowest WBC [MD=-2.26,95%C7(-3.13,-1.40), P<0.00001].Conclusion:Current evidence has showed that idarubicin combined with cytarabine in treating AML is better than daunorubicin combined with cytarabine, and the sa fty between two groups have no difference. |
PDF Full Text Request